VIDEX
LOE ApproachingNDAORALFOR SOLUTIONPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX is an oral antiretroviral solution approved in 1991 for HIV infection treatment. The drug is a small-molecule nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV replication. It represents one of the foundational antiretroviral therapies from the early HIV treatment era.
LOE Approaching
With LOE approaching and minimal Part D data visibility, the brand team is likely small and focused on managed decline rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
HIV Infections
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
Career Relevance
Working on VIDEX represents a career position in managing product obsolescence and transition planning rather than growth or innovation. Roles focus on maximizing remaining market value, managing generic transition, and potentially supporting portfolio repositioning within Bristol Myers Squibb's HIV franchise.
Brand Manager
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.